CommunitiesHER2+Has Your Doctor Switched Your Herceptin to Hercessi?

Has Your Doctor Switched Your Herceptin to Hercessi?

AV

Community Member

8 months ago

Has anyone’s doctor unilaterally changed herceptin brand with hercessi, a recently fda approved bio similar drug ?

7 comments
Comment
accepted answer

Accepted Answer

Switching from Herceptin to Hercessi is becoming more common as healthcare systems adopt biosimilar medications. Many patients in the HER2+ community have experienced similar changes, often without advance notice from their medical teams. This transition can understandably feel concerning when it happens without discussion. Consider reaching out to your oncology team to understand their reasoning and to address any questions about the switch - they can provide specific information about efficacy and monitoring protocols for biosimilars in your treatment plan.

3+ patients found this helpful

JK

Community Member

6 months ago

I could see this happening if there was an insurance change and Herceptin was no longer covered. My insurance wouldn’t cover Herceptin and I was on a biosimilar instead.

AV

Community Member

6 months ago

Did you notice any difference ? I’m apprehensive given that they contracted with a new bio similar

1
JK

Community Member

6 months ago

I was only on the biosimilar. There are several biosimilars for Herceptin. Not really sure what differences there are. I would ask your doctor why they picked that particular one.

AV

Community Member

6 months ago

Cheaper cost for insurance

JF

Community Member

6 months ago

I’m on Kanjenti biosimilar to Herceptin. Same reason…cost. I’ve been lucky so far with no issues. Going on 5th dose, so time will tell. I need to take it for a year, 21 days apart. Along with Perjeta.

1
AV

Community Member

6 months ago

Same here , since it was switched mid treatment , I’ve experienced stronger bouts of non stop diarrhea, exhausting !

1
CA

Community Member

2 months ago

Switching from Herceptin to Hercessi is becoming more common as healthcare systems adopt biosimilar medications. Many patients in the HER2+ community have experienced similar changes, often without advance notice from their medical teams. This transition can understandably feel concerning when it happens without discussion. Consider reaching out to your oncology team to understand their reasoning and to address any questions about the switch - they can provide specific information about efficacy and monitoring protocols for biosimilars in your treatment plan.

Outcomes4Me

© 2025 Outcomes4Me Inc. All rights reserved.